

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**北 斗 嘉 藥 業 股 份 有 限 公 司**  
**BAYTACARE PHARMACEUTICAL CO., LTD.\***

*(formerly known as 東北虎藥業股份有限公司 (Northeast Tiger Pharmaceutical Co., Ltd. \*))  
(a joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 8197)**

**CHANGE OF COMPANY NAME**

Reference is made to the announcement of Baytacare Pharmaceutical Co., Ltd.\* (formerly known as Northeast Tiger Pharmaceutical Co., Ltd.\*) (the “**Company**”) dated 28 November 2016 and the circular of the Company dated 29 December 2016 in relation to, among other things, the proposed change of company name (the “**Change of Company Name**”).

As announced by the Company on 16 January 2017, the ordinary resolution regarding the Change of Company Name was passed by the shareholders of the Company at the extraordinary general meeting held on 16 January 2017.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has completed the registration of change in the name of the Company from “東北虎藥業股份有限公司 (Northeast Tiger Pharmaceutical Co., Ltd. \*)” to “北斗嘉藥業股份有限公司 (Baytacare Pharmaceutical Co., Ltd. \*)”. On 24 April 2017, the Company received a new business license dated 24 April 2017 issued by Jilin Provincial Administration for Industry and Commerce\* (吉林省工商行政管理局).

The Company will proceed with all necessary filing procedures with the Companies Registry of Hong Kong as soon as practicable. Further announcement(s) will be made by the Company regarding the registration of change of corporate name of non-Hong Kong Company and change of the Company’s stock short names as and when appropriate in this regard.

By Order of the Board  
北斗嘉藥業股份有限公司  
**Baytacare Pharmaceutical Co., Ltd.\***  
*Chairman*  
**Wang Shaoyan**

Jilin, the People’s Republic of China, 24 April 2017

*As at the date of this announcement, the executive Directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the non-executive Directors are Guo Aiqun and Cao Yang and the independent non-executive Directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the website of the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited at <http://www.hkgem.com> for at least 7 days from the day of its posting and the Company’s website at <http://www.northeasttiger.com> from the date of this announcement.*

*\* For identification purpose only*